期刊: ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022; 55 (6)
Background Due to limited research on the natural history of indefinite for dysplasia (IND) and low-grade dysplasia (LGD) in inflammatory bowel diseas......
期刊: ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022; 55 (11)
Background Infantile-onset inflammatory bowel disease can be caused by defects in interleukin-10 signalling. The natural history and clinical outcomes......
期刊: ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022; 55 (6)
Background The PNPLA3 and TM6SF2 gene variants have been found to cause NAFLD with a favourable cardiovascular risk profile. Aims To investigate the e......
期刊: ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022; 55 (4)
LINKED CONTENT This article is linked to Chao et al papers. To view these articles, visit and
期刊: ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022; 55 (4)
LINKED CONTENT This article is linked to Chao et al papers. To view these articles, visit and
期刊: ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022; 55 (3)
Background While the incidence of inflammatory bowel disease (IBD) has stabilised in the West, it is still increasing in several newly industrialised ......